Vectura Chief Executive Chris Blackwell will step down from that position at the end of June 2015, the company has announced. Blackwell has been with the company since 2002. The company’s board says that it plans a search for a new chief executive.
Vectura licenses its DPI devices and formulations to numerous pharmaceutical companies, most recently announcing a partnership with Janssen Biotech on development of DPIs for asthma and COPD.
Blackwell commented, “I am intensely proud of what we have achieved over the past twelve years and I feel that now is the right time to move on. I remain totally focused on the continued evolution of Vectura and I am confident that the business is in great shape, with the right senior management team to ensure that the company continues to thrive. I would also like to take this opportunity to express my gratitude to those, past and present, who have helped build the company, to those who have supported its growth and to the Board for their understanding and support.”
Vectura Board Chairman Bruno Angelici said, “I have enjoyed working with Chris and I warmly thank him for the great results achieved under his leadership. Whilst we will be sad to see Chris depart, he will leave the business in a very strong position. On behalf of the entire Board I would like to wish him well in his future endeavors.”
Read the Vectura press release.
